Results 71 to 80 of about 4,836 (184)

Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Fabià Torres‐Betato, Lluís Puig
wiley   +1 more source

Establishing Stakeholder Priorities for Development of a Multi‐Arm Multi‐Stage Platform Trial in Crohn's Disease

JCC Plus, Volume 1, Issue 6, November 2026.
An international modified Delphi study identified stakeholder consensus on population, interventions, comparators and outcomes to inform development of a future multi‐arm, multi‐stage adaptive platform trial for Crohn's disease. ABSTRACT Background and Aims The expanding range of advanced therapies for Crohn's disease (CD) has increased complexity in ...
Shellie J. Radford, Nurulamin Noor, Daniel Lightowler, Jonathan Segal, Patricia Kelly, Shahida Din, Klaartje B. Kok, Shaji Sebastian, Peter Irving, Charles Maxwell‐Armstrong, Stuart Taylor, Rachel Cooney, James Lindsay, Bruce E. Sands, Remo Panaccione, Gordon W. Moran   +15 more
wiley   +1 more source

Successful bimekizumab retreatment after secondary failure in multi‐biologic‐resistant psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nicole Kah Mun Yoong, Melinda Withington, Francis Yi Xing Lai, Paul Curnow, Senhong Lee   +4 more
wiley   +1 more source

Risankizumab and Certolizumab Pegol Dual-Targeted Therapy for Crohn’s Disease and Axial Spondyloarthritis: A Case Report

Case Reports in Gastroenterology
Introduction: Treatment of Crohn’s disease (CD) and axial spondyloarthritis (axSpA) is challenging, with CD refractory to anti-TNF antibodies.
Anouk Lehmann, Juerg Vosbeck, Diego Kyburz, Petr Hruz, Jan Hendrik Niess   +4 more
doaj   +1 more source

Clinical Decision‐Making During Monitoring Episodes in Advanced Therapy Management for Inflammatory Bowel Disease: A National Nurse‐Led Service Evaluation

JCC Plus, Volume 1, Issue 6, November 2026.
This national, multisite, nurse‐led evaluation highlights practice patterns across UK IBD centres, revealing reliance on reactive flare‐driven treatment modification. Balancing this with structured proactive surveillance and therapeutic drug monitoring aligns with treat‐to‐target principles and supports safer advanced therapy care across diverse ...
Vida Cairnes, Dominic Devine, Susie Wen, Hayley Owen, Isobel Mason, Beverley Kirkham, Wendi Harrison, Raymoncler Diaz, Kerry Robinson, Monica Chan, Rachel Campbell, Tracey Tyrell, Lynn Gray, Michelle Clarke, Sarah Hawkins, Gaz Lloyd‐Ford, Heather Johnson, Gayle Martin, Pearl Avery   +18 more
wiley   +1 more source

Single-cell RNA sequencing and in vitro validation reveal risankizumab induces anti-inflammatory macrophage polarization in psoriasis

European Journal of Medical Research
Background Risankizumab was an approved novel drug by Japan for psoriasis, we aimed to explore its underlying therapeutic mechanism through the single-cell RNA sequencing (scRNA-seq) technology.
Yuan Yuan, Linzi Li, Lihong Yang, Jiyuan Zheng, Guang Gao, Ting Tan, Jing Liu, Wen Sun   +7 more
doaj   +1 more source

Effect of Anti‐IL‐23 and Anti‐IL‐17 Therapy on Darier Disease: A Case Series

Australasian Journal of Dermatology, Volume 67, Issue 7, Page 414-419, November 2026.
ABSTRACT Darier disease is a rare ATP2A2‐related genodermatosis for which therapeutic options remain limited, as acitretin is often constrained by toxicity and teratogenicity. In this retrospective real‐world case series of eight patients, anti‐IL‐17 therapy showed a more consistent early signal of clinical benefit than anti‐IL‐23 therapy, with greater
Maione Vincenzo, Zanghi Silvia, Catapano Cecilia, Bighetti Stefano, Cattaneo Isacco, Venturini Marina, Bettolini Luca   +6 more
wiley   +1 more source

S1‐Leitlinie: Therapie der generalisierten pustulösen Psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 11, Page 1669-1678, November 2026.
Zusammenfassung Die S1‐Leitlinie „Therapie der generalisierten pustulösen Psoriasis (GPP)“ ist eine deutsche Leitlinie, die nach den Kriterien der AWMF erstellt wurde. In der Langfassung werden Aspekte wie klinisches Bild, Pathogenese, Diagnose und Differenzialdiagnose, Begleiterkrankungen und Therapien beleuchtet.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Update on risankizumab for the treatment of moderate to severe psoriasis

, 2020
Introduction: The therapeutic landscape for psoriasis is ever-changing. Risankizumab is the newest approved biologic and one of three currently licensed that targets the p19 subunit of interleukin-23 (IL-23).
Al-Janabi, A; id_orcid, Warren, RB, Warren, RB; id_orcid, RB Warren, A Al-Janabi   +4 more
core   +1 more source

Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: a multicentric retrospective cohort study of 49 patients

, 2023
safety of risankizumab in patients with psoriasis and hepatitis B and
Battistella, Sara, Gisondi, Paolo, Martina Burlando, Dapavo, Paolo, Francesco Paolo Russo, Russo, Francesco Paolo, Riccardo Balestri, Ciolfi, Christian, Costanzo, Antonio, Stefano Piaserico, Miriam Pizzolato, Piaserico, Stefano, Karin Chersi, Antonio Costanzo, Piergiorgio Malagoli, Balestri, Riccardo, Chersi, Karin, Pizzolato, Miriam, Bardazzi, Federico, Burlando, Martina, Paolo Dapavo, Rech, Giulia, Christian Ciolfi, Malagoli, Piergiorgio, Federico Bardazzi, Giulia Rech, Sara Battistella, Paolo Gisondi   +27 more
core   +1 more source